EPISODE · Mar 22, 2017 · 9 MIN
Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma
from Journal of Clinical Oncology (JCO) Podcast · host Amanda Psyrri
By Amanda Psyrri The findings of KEYNOTE-055 are summarized and compared to other immunotherapy studies in recurrent/metastatic head and neck squamous cell carcinoma. Related Article: Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
NOW PLAYING
Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m